Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies

References

• JemalASiegelRWardECancer statistics, 2009CA Cancer J Clin200959422524919474385
   PubMed Web of Science ®Google Scholar
• CannistraSACancer of the ovaryN Engl J Med2004351242519252915590954
   PubMed Web of Science ®Google Scholar
• GadducciALandoniFMagginoTSerum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian studyInt J Gynecol Cancer199771788312795808
   PubMed Web of Science ®Google Scholar
• HeintzAPOdicinoFMaisonneuvePCarcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological CancerInt J Gynaecol Obstet200695Suppl 1S161S19217161157
   PubMed Web of Science ®Google Scholar
• ThigpenJTBlessingJABallHHummelSJBarrettRJPhase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group studyJ Clin Oncol1994129174817537916038
   PubMed Web of Science ®Google Scholar
• UshijimaKTreatment for recurrent ovarian cancer-at first relapseJ Oncol2010497429
   Google Scholar
• MonkBJColemanRLChanging the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compoundsInt J Gynecol Cancer200919Suppl 2S63S6719955917
   PubMed Web of Science ®Google Scholar
• Gonzalez-MartinAJCalvoEBoverIRandomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) studyAnn Oncol200516574975515817604
   PubMed Web of Science ®Google Scholar
• PfistererJPlanteMVergoteIGemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJ Clin Oncol200624294699470716966687
   PubMed Web of Science ®Google Scholar
• AlbertsDSLiuPYWilczynskiSPRandomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)Gynecol Oncol20081081909417949799
   PubMed Web of Science ®Google Scholar
• SpriggsDOptimal sequencing in the treatment of recurrent ovarian cancerGynecol Oncol2003903 pt 2S39S4413129495
   PubMed Web of Science ®Google Scholar
• MarkmanMOptimal management of recurrent ovarian cancerInt J Gynecol Cancer200919Suppl 2S40S4319955913
   PubMed Web of Science ®Google Scholar
• HerzogTJRecurrent ovarian cancer: how important is it to treat to disease progression?Clin Cancer Res200410227439744915569973
   PubMed Web of Science ®Google Scholar
• CreeIAKurbacherCMLamontAHindleyACLoveSA prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician’s choice in patients with recurrent platinum-resistant ovarian cancerAnticancer Drugs20071891093110117704660
   PubMed Web of Science ®Google Scholar
• SchragDGarewalHSBursteinHJAmerican Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assaysJ Clin Oncol200422173631363815289488
   PubMed Web of Science ®Google Scholar
• GordonANGranaiCORosePGPhase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancerJ Clin Oncol200018173093310010963637
   PubMed Web of Science ®Google Scholar
• MuggiaFMHainsworthJDJeffersSPhase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulationJ Clin Oncol19971539879939060537
   PubMed Web of Science ®Google Scholar
• MonkBJHerzogTJKayeSBTrabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancerJ Clin Oncol201028193107311420516432
   PubMed Web of Science ®Google Scholar
• HavrileskyLJAlvarezAASayerRAWeekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancerGynecol Oncol2003881515712504627
   PubMed Web of Science ®Google Scholar
• RosePGBlessingJABallHGA phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group studyGynecol Oncol200388213013512586591
   PubMed Web of Science ®Google Scholar
• MarkmanMWebsterKZanottiKPhase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancerGynecol Oncol200390359359613678730
   PubMed Web of Science ®Google Scholar
• MutchDGOrlandoMGossTRandomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerJ Clin Oncol200725192811281817602086
   PubMed Web of Science ®Google Scholar
• BookmanMAMalmstromHBolisGTopotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxelJ Clin Oncol19981610334533529779711
   PubMed Web of Science ®Google Scholar
• SafraTMenczerJBernsteinREfficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancerGynecol Oncol2007105120521017239430
   PubMed Web of Science ®Google Scholar
• RosePGBlessingJAMayerARHomesleyHDProlonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group studyJ Clin Oncol19981624054109469322
   PubMed Web of Science ®Google Scholar
• BodurkaDCLevenbackCWolfJKPhase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancerJ Clin Oncol200321229129712525521
   PubMed Web of Science ®Google Scholar
• SorensenPHoyerMJakobsenAPhase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinomaGynecol Oncol2001811586211277650
   PubMed Web of Science ®Google Scholar
• MarkmanMHakesTReichmanBIfosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant diseaseJ Clin Oncol19921022432481732425
   PubMed Web of Science ®Google Scholar
• PrefontaineMDonovanJTPowellJLBuleyLTreatment of refractory ovarian cancer with 5-fluorouracil and leucovorinGynecol Oncol19966122492528626142
   PubMed Web of Science ®Google Scholar
• KowalskiRJGiannakakouPHamelEActivities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R))J Biol Chem19972724253425418999970
   PubMed Web of Science ®Google Scholar
• De GeestKBlessingJAMorrisRTPhase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group studyJ Clin Oncol281149153
   PubMed Web of Science ®Google Scholar
• CarterNJKeamSJTrabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancerDrugs200767152257227617927287
   PubMed Web of Science ®Google Scholar
• KrasnerCNMcMeekinDSChanSA Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimensBr J Cancer200797121618162418000504
   PubMed Web of Science ®Google Scholar
• ShihCChenVJGossettLSLY231514, a pyrrolo[2,3-d]-pyrimidine-based antifolate that inhibits multiple folate-requiring enzymesCancer Res19975761116111239067281
   PubMed Web of Science ®Google Scholar
• MillerDSBlessingJAKrasnerCNPhase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology GroupJ Clin Oncol200927162686269119332726
   PubMed Web of Science ®Google Scholar
• KamsteegMRutherfordTSapiEPhenoxodiol–an isoflavone analog–induces apoptosis in chemoresistant ovarian cancer cellsOncogene200322172611262012730675
   PubMed Web of Science ®Google Scholar
• AlveroABO’MalleyDBrownDMolecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cellsCancer2006106359960816388521
   PubMed Web of Science ®Google Scholar
• FracassoPMBlessingJAMorganMASoodAKHoffmanJSPhase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group studyJ Clin Oncol200321152856285912885801
   PubMed Web of Science ®Google Scholar
• PectasidesDPectasidesMFarmakisDOxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II studyGynecol Oncol200495116517215385127
   PubMed Web of Science ®Google Scholar
• FaivreSKallaSCvitkovicEOxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experienceAnn Oncol19991091125112810572615
   PubMed Web of Science ®Google Scholar
• RecchiaFSaggioGAmiconiGA multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancerGynecol Oncol2007106116416917481704
   PubMed Web of Science ®Google Scholar
• GermanoDRosatiGManzioneLGemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experienceJ Chemother200719557758118073158
   PubMed Web of Science ®Google Scholar
• WosikowskiKLamphereLUntereggerGPreclinical antitumor activity of the oral platinum analog satraplatinCancer Chemother Pharmacol200760458960017541592
   PubMed Web of Science ®Google Scholar
• SteinmanRMDendritic cells: understanding immunogenicityEur J Immunol200737Suppl 1S53S6017972346
   PubMed Web of Science ®Google Scholar
• ZhangLConejo-GarciaJRKatsarosDIntratumoral T cells, recurrence, and survival in epithelial ovarian cancerN Engl J Med2003348320321312529460
   PubMed Web of Science ®Google Scholar
• SatoEOlsonSHAhnJIntraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancerProc Natl Acad Sci U S A200510251185381854316344461
   PubMed Web of Science ®Google Scholar
• CurielTJCoukosGZouLSpecific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNat Med200410994294915322536
   PubMed Web of Science ®Google Scholar
• LiuBNashJRunowiczCOvarian cancer immunotherapy: opportunities, progresses and challengesJ Hematol Oncol20103720146807
   PubMed Web of Science ®Google Scholar
• CheeverMAAllisonJPFerrisASThe prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational researchClin Cancer Res200915175323533719723653
   PubMed Web of Science ®Google Scholar
• HirdVMaraveyasASnookDAdjuvant therapy of ovarian cancer with radioactive monoclonal antibodyBr J Cancer19936824034068347497
   PubMed Web of Science ®Google Scholar
• NicholsonSBomphrayCCThomasHA phase I trial of idiotypic vaccination with HMFG1 in ovarian cancerCancer Immunol Immunother200453980981615127236
   PubMed Web of Science ®Google Scholar
• OeiALVerheijenRHSeidenMVDecreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survivalInt J Cancer2007120122710271417354223
   PubMed Web of Science ®Google Scholar
• EhlenTGHoskinsPJMillerDA pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancerInt J Gynecol Cancer20051561023103416343178
   PubMed Web of Science ®Google Scholar
• GordonANSchultesBCGallionHCA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patientsGynecol Oncol200494234035115297171
   PubMed Web of Science ®Google Scholar
• PfistererJdu BoisASehouliJThe anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVARAnn Oncol200617101568157717005631
   PubMed Web of Science ®Google Scholar
• ReinartzSKohlerSSchlebuschHVaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II)Clin Cancer Res20041051580158715014007
   PubMed Web of Science ®Google Scholar
• SabbatiniPDupontJAghajanianCPhase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancerClin Cancer Res200612185503551017000686
   PubMed Web of Science ®Google Scholar
• ConnorJBannerjiRSaitoSRegression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cellsJ Exp Med19931774112711348459207
   PubMed Web of Science ®Google Scholar
• VladAMBudiuRALenznerDEA phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancerCancer Immunol Immunother2009 [Epub ahead of print]
   Google Scholar
• RocheMRRuddPJKrasnerCNPhase II trial of GM-CSF in women with asymptomatic recurrent mullerian tumorsGynecol Oncol2010116216817219922985
   PubMed Web of Science ®Google Scholar
• SchmelerKMVadhan-RajSRamirezPTA phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancerGynecol Oncol2009113221021519264351
   PubMed Web of Science ®Google Scholar
• KaurTSlavcevRAWettigSDAddressing the challenge: current and future directions in ovarian cancer therapyCurr Gene Ther20099643445820021329
   PubMed Web of Science ®Google Scholar
• QianHNLiuGZCaoSJFengJYeXThe experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN-gamma genesInt J Gynecol Cancer2002121808511860540
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDIMPACT Study InvestigatorsSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• CannonMJO’BrienTJCellular immunotherapy for ovarian cancerExpert Opin Biol Ther2009966778819456205
   PubMed Web of Science ®Google Scholar
• BrossartPWirthsSStuhlerGInduction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cellsBlood20009693102310811049990
   PubMed Web of Science ®Google Scholar
• HernandoJJParkTWKublerKVaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trialCancer Immunol Immunother2002511455211845259
   PubMed Web of Science ®Google Scholar
• RosenbergSARestifoNPYangJCMorganRADudleyMEAdoptive cell transfer: a clinical path to effective cancer immunotherapyNat Rev Cancer20088429930818354418
   PubMed Web of Science ®Google Scholar
• DudleyMEWunderlichJRYangJCAdoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomaJ Clin Oncol200523102346235715800326
   PubMed Web of Science ®Google Scholar
• AokiYTakakuwaKKodamaSUse of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancerCancer Res1991517193419392004379
   PubMed Web of Science ®Google Scholar
• CarpenitoCMiloneMCHassanRControl of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domainsProc Natl Acad Sci U S A200910693360336519211796
   PubMed Web of Science ®Google Scholar
• KershawMHWestwoodJAParkerLLA phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancerClin Cancer Res20061220 pt 16106611517062687
   PubMed Web of Science ®Google Scholar
• HodiFSButlerMObleDAImmunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsProc Natl Acad Sci U S A200810583005301018287062
   PubMed Web of Science ®Google Scholar
• BarnettBKryczekIChengPZouWCurielTJRegulatory T cells in ovarian cancer: biology and therapeutic potentialAm J Reprod Immunol200554636937716305662
   PubMed Web of Science ®Google Scholar
• MarkmanMAntiangiogenic drugs in ovarian cancerExpert Opin Pharmacother200910142269227719671017
   PubMed Web of Science ®Google Scholar
• Abu-JawdehGMFaixJDNiloffJStrong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasmsLab Invest1996746110511158667614
   PubMed Web of Science ®Google Scholar
• CooperBCRitchieJMBroghammerCLPreoperative serum vascular endothelial growth factor levels: significance in ovarian cancerClin Cancer Res20028103193319712374688
   PubMed Web of Science ®Google Scholar
• RaspolliniMRAmunniGVillanucciAPrognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinomaInt J Gynecol Cancer200414581582315361189
   PubMed Web of Science ®Google Scholar
• BurgerRASillMWMonkBJGreerBESoroskyJIPhase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyJ Clin Oncol200725335165517118024863
   PubMed Web of Science ®Google Scholar
• CannistraSAMatulonisUAPensonRTPhase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerJ Clin Oncol200725335180518618024865
   PubMed Web of Science ®Google Scholar
• ChengXMoroneyJWLevenbackCFWhat is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?J Chemother200921556657219933049
   PubMed Web of Science ®Google Scholar
• GarciaAAHirteHFlemingGPhase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortiaJ Clin Oncol2008261768218165643
   PubMed Web of Science ®Google Scholar
• CamidgeDREckhardtSGDiabSA phase I dose-escalation study of weekly IMC-1121B. a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancerJ Clin Oncol200624185 (June 20 Suppl)303216809727
   PubMed Web of Science ®Google Scholar
• A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaAccessed 2010 Aug 11 http://clinicaltrials.gov/ct2/show/NCT00721162
   Google Scholar
• LedermannJARajaFATargeted trials in ovarian cancerGynecol Oncol2010119115115620591473
   PubMed Web of Science ®Google Scholar
• TewWColomboNRay-CaquardIVEGF-Trap for patients with recurrent platinum resistant epithelial ovarian cancerJ Clin Oncol20082518S Abstract 14598
   Google Scholar
• WedgeSRKendrewJHennequinLFAZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerCancer Res200565104389440015899831
   PubMed Web of Science ®Google Scholar
• HerbstRSShinDMMonoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapyCancer20029451593161111920518
   PubMed Web of Science ®Google Scholar
• LafkyJMWilkenJABaronATMaihleNJClinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancerBiochim Biophys Acta20081785223226518291115
   PubMed Web of Science ®Google Scholar
• SchilderRJPathakHBLokshinAEPhase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rashGynecol Oncol20091131212719162309
   PubMed Web of Science ®Google Scholar
• WuMRivkinAPhamTPanitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancerClin Ther2008301143018343240
   PubMed Web of Science ®Google Scholar
• SmithIProcterMGelberRD2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialLancet20073699555293617208639
   PubMed Web of Science ®Google Scholar
• SlamonDJGodolphinWJonesLAStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience198924449057077122470152
   PubMed Web of Science ®Google Scholar
• BookmanMADarcyKMClarke-PearsonDBoothbyRAHorowitzIREvaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology GroupJ Clin Oncol200321228329012525520
   PubMed Web of Science ®Google Scholar
• MakhijaSAmlerLCGlennDClinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancerJ Clin Oncol2871215122319901115
   PubMed Web of Science ®Google Scholar
• SchilderRJSillMWChenXPhase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group StudyClin Cancer Res200511155539554816061871
   PubMed Web of Science ®Google Scholar
• PosadasEMLielMSKwitkowskiVA phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancerCancer200710971323133017330838
   PubMed Web of Science ®Google Scholar
• HirteHOzaASwenertonKA phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)Gynecol Oncol118330831220646751
   PubMed Web of Science ®Google Scholar
• ApteSMBucanaCDKillionJJGershensonDMFidlerIJExpression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell linesGynecol Oncol2004931788615047217
   PubMed Web of Science ®Google Scholar
• SchilderRJSillMWLeeRBPhase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group StudyJ Clin Oncol200826203418342518612157
   PubMed Web of Science ®Google Scholar
• ColemanRLBroaddusRRBodurkaDCPhase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancersGynecol Oncol2006101112613116271384
   PubMed Web of Science ®Google Scholar
• BiagiJJOzaAMChalchalHIA phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group StudyAnn Oncol2010 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• FriedlanderMHancockKCRischinDA Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancerGynecol Oncol20101191323720584542
   PubMed Web of Science ®Google Scholar
• KalliKRMORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancerCurr Opin Investig Drugs200781210671073
   PubMedGoogle Scholar
• WeitmanSDLarkRHConeyLRDistribution of the folate receptor GP38 in normal and malignant cell lines and tissuesCancer Res19925212339634011596899
   PubMed Web of Science ®Google Scholar
• ChungMKHanSSRohJKSynergistic embryotoxicity of combination pyrimethamine and folic acid in ratsReprod Toxicol1993754634688274822
   PubMed Web of Science ®Google Scholar
• MolthoffCFPrinssenHMKenemansPEscalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I studyCancer199780Suppl 12271227209406729
   PubMed Web of Science ®Google Scholar
• Van Zanten-PrzybyszIMolthoffCGebbinckJKCellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot studyJ Cancer Res Clin Oncol2002128948449212242512
   PubMed Web of Science ®Google Scholar
• ColivaAZacchettiALuisonE90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomasCancer Immunol Immunother200554121200121315926078
   PubMed Web of Science ®Google Scholar
• ZacchettiAColivaALuisonE(177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenograftsNucl Med Biol200936775977019720288
   PubMed Web of Science ®Google Scholar
• EbelWRouthierELFoleyBPreclinical evaluation of MORAb- 003, a humanized monoclonal antibody antagonizing folate receptor-alphaCancer Immun20077617346028
   PubMedGoogle Scholar
• AhmedSGerstSVander ElsNPezzuliSSabbatiniPHensleyMDupontJPhase I Study of MORAb-003, a humanized anti-folate receptor-alpha, monoclonal antibody, in platinum resistant ovarian cancerProc Am Soc Clin Oncol200625 Abstract # 5027
   Web of Science ®Google Scholar
• PhilipsMArmstrongDColemanRNovel phase II study design of MORAb-003, a monoclonal antibody against folate receptor alpha in platinum-sensitive ovarian cancer in first relapseProc Am Soc Clinc Oncol200743 Abstract # 5583
   Google Scholar
• WentPTLugliAMeierSFrequent EpCam protein expression in human carcinomasHum Pathol200435112212814745734
   PubMed Web of Science ®Google Scholar
• BelloneSSiegelERCoccoEOverexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapyInt J Gynecol Cancer200919586086619574774
   PubMed Web of Science ®Google Scholar
• RufPLindhoferHInduction of a long-lasting antitumor immunity by a trifunctional bispecific antibodyBlood20019882526253411588051
   PubMed Web of Science ®Google Scholar
• HeissMMMurawaPKoralewskiPThe trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialInt J Cancer201012792209222120473913
   PubMed Web of Science ®Google Scholar
• HassanRBullockSPremkumarAPhase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancersClin Cancer Res200713175144514917785569
   PubMed Web of Science ®Google Scholar
• Oral contraceptive use and the risk of ovarian cancerThe Centers for Disease Control Cancer and Steroid Hormone StudyJAMA198324912159615996338264
   PubMed Web of Science ®Google Scholar
• O’DonnellAJMacleodKGBurnsDJSmythJFLangdonSPEstrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogenEndocr Relat Cancer200512485186616322326
   PubMed Web of Science ®Google Scholar
• WilliamsCJTamoxifen for relapse of ovarian cancerCochrane Database Syst Rev20011CD00103411279703
   PubMedGoogle Scholar
• RamirezPTSchmelerKMMilamMREfficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneumGynecol Oncol20081101565918457865
   PubMed Web of Science ®Google Scholar
• SmythJFGourleyCWalkerGAntiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patientsClin Cancer Res200713123617362217575226
   PubMed Web of Science ®Google Scholar
• ArgentaPAThomasSGJudsonPLA phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancerGynecol Oncol2009113220520919239974
   PubMed Web of Science ®Google Scholar
• RoceretoTFBradyWEShahinMSA phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group studyGynecol Oncol201016333233419922989
   PubMed Web of Science ®Google Scholar
• BalbiGPianoLDCardoneACirelliGSecond-line therapy of advanced ovarian cancer with GnRH analogsInt J Gynecol Cancer200414579980315361187
   PubMed Web of Science ®Google Scholar
• HasanJTonNMullamithaSPhase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancerBr J Cancer200593664765116222310
   PubMed Web of Science ®Google Scholar
• VerschraegenCFWestphalenSHuWPhase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancerGynecol Oncol200390355255913678723
   PubMed Web of Science ®Google Scholar
• D’AndreaADGrompeMThe Fanconi anaemia/BRCA pathwayNat Rev Cancer200331233412509764
   PubMed Web of Science ®Google Scholar
• PalTPermuth-WeyJBettsJABRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma casesCancer2005104122807281616284991
   PubMed Web of Science ®Google Scholar
• McCabeNTurnerNCLordCJDeficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibitionCancer Res200666168109811516912188
   PubMed Web of Science ®Google Scholar
• KonstantinopoulosPASpentzosDKarlanBYGene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancerJ Clin Oncol201028223555356120547991
   PubMed Web of Science ®Google Scholar
• AudehMWCarmichaelJPensonRTOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialLancet2010376973724525120609468
   PubMed Web of Science ®Google Scholar